Informační systém MU
CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK, M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS a P. GHIA. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 12, s. 3444-3454. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-021-01450-8.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Autoři CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK (203 Česká republika, domácí), M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS a P. GHIA.
Vydání Leukemia, London, Nature Publishing Group, 2021, 0887-6924.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 12.883
Kód RIV RIV/00216224:14110/21:00123869
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1038/s41375-021-01450-8
UT WoS 000713599200001
Klíčová slova anglicky COVID-19; severity; mortality; CLL
Štítky 14110212, 14110323, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 20. 1. 2022 14:42.
Anotace
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
Zobrazeno: 18. 8. 2024 04:16